Cunshan Wang

5.8k total citations · 5 hit papers
88 papers, 3.9k citations indexed

About

Cunshan Wang is a scholar working on Mechanical Engineering, Rheumatology and Materials Chemistry. According to data from OpenAlex, Cunshan Wang has authored 88 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Mechanical Engineering, 31 papers in Rheumatology and 19 papers in Materials Chemistry. Recurrent topics in Cunshan Wang's work include Rheumatoid Arthritis Research and Therapies (27 papers), High Entropy Alloys Studies (26 papers) and Spondyloarthritis Studies and Treatments (21 papers). Cunshan Wang is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (27 papers), High Entropy Alloys Studies (26 papers) and Spondyloarthritis Studies and Treatments (21 papers). Cunshan Wang collaborates with scholars based in United States, China and Canada. Cunshan Wang's co-authors include Sujatha Menon, Keith S. Kanik, Carol A. Connell, Jose L. Rivas, Deepak L. Bhatt, Steven R. Ytterberg, Gary G. Koch, Thijs Hendrikx, Ted R. Mikuls and Andrea Shapiro and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Cunshan Wang

87 papers receiving 3.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

2022 963 citations Steven R. Ytterberg, Deepak L. Bhatt et al. profile →
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

2017 421 citations Philip J. Mease, Oliver FitzGerald et al. profile →
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors

2017 378 citations Dafna D. Gladman, William F. C. Rigby et al. profile →
Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

2021 159 citations Atul Deodhar, Huji Xu et al. Annals of the Rheumatic Diseases profile →
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance

2022 123 citations Christina Charles‐Schoeman, Deepak L. Bhatt et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Cunshan Wang

Since Specialization

Citations

This map shows the geographic impact of Cunshan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cunshan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cunshan Wang more than expected).

Fields of papers citing papers by Cunshan Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cunshan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cunshan Wang. The network helps show where Cunshan Wang may publish in the future.

Co-authorship network of co-authors of Cunshan Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Cunshan Wang. A scholar is included among the top collaborators of Cunshan Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cunshan Wang. Cunshan Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of slip and twinning on texture evolution mechanisms in dual-phase titanium alloys 2025 ·Journal of Materials Research and Technology ·(unknown), (unknown), (unknown), Jinhu Zhang, (unknown), Cunshan Wang, Rui Yang	1
2	Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients 2024 ·Arthritis & Rheumatology ·Christina Charles‐Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, Cunshan Wang, Ted R. Mikuls, (unknown), Carol A. Connell, John Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz	13
3	Integrated safety analysis of tofacitinib from Phase 2 and 3 trials of patients with ankylosing spondylitis 2024 ·Advances in Rheumatology ·Atul Deodhar, Servet Akar, Jeffrey R. Curtis, Bassel Elzorkany, Marina Magrey, Cunshan Wang, Joseph Wu, Solomon B. Makgoeng, Ivana Vranić, Sujatha Menon, Dona Fleishaker, (unknown), Lara Fallon, Arne Yndestad, Robert Landewé	1
4	Tofacitinib Reduces Spinal Inflammation in Vertebral Bodies and Posterolateral Elements in Ankylosing Spondylitis: Results from a Phase 2 Trial 2023 ·Rheumatology and Therapy ·Mikkel Østergaard, Joseph Wu, Lara Fallon, Sarah P. Sherlock, Cunshan Wang, Dona Fleishaker, Keith S. Kanik, Walter P. Maksymowych	2
5	Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance 2023 ·Therapeutic Advances in Musculoskeletal Disease ·George Karpouzas, Zoltán Szekanecz, Eva Baecklund, Ted R. Mikuls, Deepak L. Bhatt, Cunshan Wang, (unknown), Yan Chen, Sujatha Menon, Carol A. Connell, Steven R. Ytterberg, (unknown)	16
6	Microstructure and Properties of Ti-Zr-Mo Alloys Fabricated by Laser Directed Energy Deposition 2023 ·Materials ·Jingtao Zhang, Cunshan Wang, (unknown)	5
7	Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study 2023 ·RMD Open ·Xiaomei Leng, Wei Lin, Shixue Liu, Keith S. Kanik, Cunshan Wang, Weiguo Wan, Zhenyu Jiang, Yi Liu, Shengyun Liu, Zhuoli Zhang, Zhiyi Zhang, Jian Xu, (unknown), (unknown), Jingyang Li, (unknown), Levent Mert Günay, Oluwaseyi Dina, (unknown), Xiaofeng Zeng	15
8	Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance 2023 ·Annals of the Rheumatic Diseases ·Lars Erik Kristensen, Silvio Danese, (unknown), Cunshan Wang, (unknown), Irene Modesto, Jose L. Rivas, Birgitta Benda	72
9	Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study breakdown → 2021 ·Annals of the Rheumatic Diseases ·Atul Deodhar, (unknown), Huji Xu, Xenofon Baraliakos, Lianne S. Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang, Oluwaseyi Dina, Lara Fallon, Keith S. Kanik, Désirée van der Heijde	159
10	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study 2021 ·The Lancet Rheumatology ·Peter Nash, Laura C. Coates, Dona Fleishaker, Alan Kivitz, Philip J. Mease, Dafna D. Gladman, Oliver FitzGerald, Cunshan Wang, Joseph Wu, Ming‐Ann Hsu, Sujatha Menon, Lara Fallon, Keith S. Kanik	27
11	Optimization of laser repair parameters for precracked 304 stainless steel components with nanocomposites addition 2020 ·Proceedings of the Institution of Mechanical Engineers Part L Journal of Materials Design and Applications ·Wei Jiang, Yinyin Li, (unknown), (unknown), Qun Yu, Cunshan Wang	2
12	Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance 2020 ·The Lancet Rheumatology ·Peter Nash, Philip J. Mease, Dona Fleishaker, Joseph Wu, Laura C. Coates, Frank Behrens, Dafna D. Gladman, Alan Kivitz, James Cheng‐Chung Wei, I. V. Shirinsky, Sujatha Menon, (unknown), Lara Fallon, Ming‐Ann Hsu, Cunshan Wang, Keith S. Kanik	15
13	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data 2020 ·Drug Safety ·Gerd R Burmester, Jeffrey R. Curtis, Huifeng Yun, Oliver FitzGerald, Kevin Winthrop, Valderílio Feijó Azevedo, William F. C. Rigby, Keith S. Kanik, Cunshan Wang, Pinaki Biswas, Thomas V. Jones, (unknown), Thijs Hendrikx, Sujatha Menon, Ricardo Rojo	34
14	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab 2019 ·The Journal of Rheumatology ·Désirée van der Heijde, Dafna D. Gladman, Oliver FitzGerald, Arthur Kavanaugh, Daniela Graham, Cunshan Wang, Lara Fallon	39
15	Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis 2018 ·Queensland's institutional digital repository (The University of Queensland) ·Gerd R Burmester, William F. C. Rigby, Ernest Choy, Peter Nash, Kevin Winthrop, Philip J. Mease, (unknown), Thijs Hendrikx, Cunshan Wang, Sujatha Menon, Daniela Graham	1
16	Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis 2018 ·Queensland's institutional digital repository (The University of Queensland) ·William F. C. Rigby, Gerd R Burmester, Oliver FitzGerald, Valderílio Feijó Azevedo, Peter Nash, Thijs Hendrikx, Daniela Graham, Cunshan Wang, Thomas V. Jones	1
17	Influence of Y 2 O 3 Content on Microstructure and Properties of Laser Alloying WC/Ni Metal Ceramic on 38CrMoAl Steel 2017 ·Cailiao gongcheng ·Liying Han, Cunshan Wang, (unknown)	1
18	Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, up to 36 Months in Patients with Active Psoriatic Arthritis: Data from the Second Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study 2017 ·Queensland's institutional digital repository (The University of Queensland) ·Peter Nash, Laura C. Coates, Alan Kivitz, Philip J. Mease, Dafna D. Gladman, (unknown), Dona Fleishaker, Cunshan Wang, Elizabeth M. Kudlacz, Sujatha Menon, Thijs Hendrikx, Keith S. Kanik	2
19	Experimental study on laser bending of shipbuilding steel plate 2005 ·Duanya jishu ·Cunshan Wang	1
20	Structure and Property of Nitriding Layer on Titanium Alloy by Laser 2003 ·Heat treatment of metals ·Cunshan Wang	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact